Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melatonin in Diabetic Retinopathy
NCT03478306Phase 3Completed
- Sponsor
- Rigshospitalet Glostrup
- Start
- Mar 2018
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diabetic retinopathy (DR) and circadian rhythm sleep disorder (CRSD) comparing Melatonin First with Placebo First (2 arms). Primary endpoint: Progression of diabetic retinopathy, oscillatory potential at 3 weeks. Started Mar 2018; status: completed.
02
Drugs
melatonin
03
Conditions
diabetic retinopathy (DR)circadian rhythm sleep disorder (CRSD)
Beyond the preview
Go deeper on NCT03478306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03478306.